Linda Beenet1, Diego Tonesi2. 1. Department of Pathology & Laboratory Medicine, University of California Los Angeles (UCLA) Technology Center for Genomics & Bioinformatics, Los Angeles, CA, USA. 2. Gastroenterology and Endoscopy Unit, Ospedale Maggiore Policlinico, Milan, Italy.
Dear Editor,We read, with great interest, the comprehensive review by Villavicencio Kim J and Wu GY that systematically addressed the issue of liver enzyme elevation in celiac disease (CD) patients.1The Authors reviewed, in detail, the most relevant studies reporting the frequency of liver enzyme elevation in CD patients and the possible causes, discussing the hypothesis that this elevation may be a clue to associated liver disease or an epiphenomenon, possibly secondary to the increased intestinal permeability that is known to characterize CD patients, especially at diagnosis, before starting a gluten-free diet.2We would like to add some considerations that, in our opinion, could have implications in the pathogenesis of hepatic injury in CD.As known, it has been reported that CD is frequently associated with other extraintestinal autoimmune diseases or even with the mere presence of autoantibodies without concomitant autoimmune pathology.3–6Among the autoimmune diseases potentially associated with CD, autoimmune hepatitis (AIH) is worthy of mention, as previously reported.1,3,7Of considerable interest, it has been reported that celiac patients frequently have anti-filamentous actin IgA antibodies that have shown reliable and significant correlation with villous atrophy.8 These autoantibodies, although of IgG class, are also known to have very high specificity for AIH.7,9This similarity between the two autoimmune diseases could be a clue that also supports possible immune-mediated pathogenesis of hypertransaminasemia in CD patients. Therefore, it would be relevant and worthy of study to analyze the presence of anti-actin antibodies in CD patients to verify whether these antibodies are markers of liver injury.Finally, it should not be overlooked, the very remarkable issue of the potential development of hepatic steatosis, which, as appropriately mentioned by the Authors, is not uncommon in CD patients with celiac disease after starting a gluten-free diet.10
Authors: A Granito; P Muratori; F Cassani; G Pappas; L Muratori; D Agostinelli; L Veronesi; R Bortolotti; N Petrolini; F B Bianchi; U Volta Journal: Clin Exp Immunol Date: 2004-08 Impact factor: 4.330
Authors: A Granito; D Zauli; P Muratori; L Muratori; A Grassi; R Bortolotti; N Petrolini; L Veronesi; P Gionchetti; F B Bianchi; U Volta Journal: Aliment Pharmacol Ther Date: 2005-04-01 Impact factor: 8.171
Authors: A Granito; L Muratori; P Muratori; G Pappas; M Guidi; F Cassani; U Volta; A Ferri; M Lenzi; F B Bianchi Journal: J Clin Pathol Date: 2006-03 Impact factor: 3.411
Authors: F Tovoli; G Negrini; R Farì; E Guidetti; C Faggiano; L Napoli; L Bolondi; A Granito Journal: Aliment Pharmacol Ther Date: 2018-07-08 Impact factor: 8.171
Authors: U Volta; R De Giorgio; A Granito; V Stanghellini; G Barbara; P Avoni; R Liguori; N Petrolini; E Fiorini; P Montagna; R Corinaldesi; F B Bianchi Journal: Dig Liver Dis Date: 2006-02-07 Impact factor: 4.088
Authors: Alessandro Granito; Paolo Muratori; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Marco Lenzi; Francesco B Bianchi; Luigi Muratori Journal: Mini Rev Med Chem Date: 2009-06 Impact factor: 3.862